News from tibotec therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 20, 2011, 02:35 ET FDA Approves EDURANT™ (rilpivirine) for Use in Treatment-Naive Adults With HIV-1

The US Food and Drug Administration (FDA) today approved EDURANT™ (rilpivirine) tablets for use in combination with other antiretroviral agents...


Jan 27, 2011, 08:53 ET Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited,...


Jan 03, 2011, 08:45 ET FDA Approves New Dosage Strength for INTELENCE®

The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside...


Dec 13, 2010, 06:37 ET FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has...


Dec 01, 2010, 08:45 ET Tibotec Therapeutics Announces Recipients of LINCC™ Funding Initiative

Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, today announced the funding recipients of the LINCC™...


Sep 20, 2010, 05:00 ET Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine

Data from the GRACE (Gender, Race And Clinical Experience) study will be published in the September 21st issue of the Annals of Internal Medicine....


May 27, 2010, 08:00 ET Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., today announced the launch of the HIV Case Manager Portal (the Portal), a...


Feb 17, 2010, 04:10 ET New Study Compares Efficacy and Safety of Once-Daily Versus Twice-Daily PREZISTA(R) Regimen in Treatment-Experienced Adult Patients With No PREZISTA Mutations

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of...


Jan 28, 2010, 08:30 ET U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir)...